Bio Plus (A099430) Stock Overview
Engages in the research and development, production, and sale of bio products in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
A099430 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Bio Plus Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩5,630.00 |
| 52 Week High | ₩8,420.00 |
| 52 Week Low | ₩4,845.00 |
| Beta | 0.53 |
| 1 Month Change | -9.49% |
| 3 Month Change | -6.48% |
| 1 Year Change | 1.44% |
| 3 Year Change | -28.64% |
| 5 Year Change | n/a |
| Change since IPO | -30.60% |
Recent News & Updates
Bio Plus' (KOSDAQ:099430) Dividend Will Be ₩50.00
Nov 10
Bio Plus (KOSDAQ:099430) Seems To Use Debt Quite Sensibly
Aug 18Recent updates
Bio Plus' (KOSDAQ:099430) Dividend Will Be ₩50.00
Nov 10Bio Plus (KOSDAQ:099430) Seems To Use Debt Quite Sensibly
Aug 18Capital Allocation Trends At Bio Plus (KOSDAQ:099430) Aren't Ideal
Jul 22What Bio Plus Co., Ltd's (KOSDAQ:099430) 26% Share Price Gain Is Not Telling You
May 09Bio Plus' (KOSDAQ:099430) Anemic Earnings Might Be Worse Than You Think
Mar 31Does Bio Plus (KOSDAQ:099430) Have A Healthy Balance Sheet?
Feb 14Bio Plus Co., Ltd's (KOSDAQ:099430) Shares Climb 30% But Its Business Is Yet to Catch Up
Jan 07Bio Plus (KOSDAQ:099430) Is Reinvesting At Lower Rates Of Return
Dec 15Bio Plus Co., Ltd's (KOSDAQ:099430) Shareholders Might Be Looking For Exit
Nov 23Earnings Not Telling The Story For Bio Plus Co., Ltd (KOSDAQ:099430) After Shares Rise 29%
Jul 23The Returns On Capital At Bio Plus (KOSDAQ:099430) Don't Inspire Confidence
Jul 05More Unpleasant Surprises Could Be In Store For Bio Plus Co., Ltd's (KOSDAQ:099430) Shares After Tumbling 31%
Jun 08Additional Considerations Required While Assessing Bio Plus' (KOSDAQ:099430) Strong Earnings
Mar 26Shareholder Returns
| A099430 | KR Medical Equipment | KR Market | |
|---|---|---|---|
| 7D | -9.0% | 0.6% | -3.3% |
| 1Y | 1.4% | -2.8% | 56.1% |
Return vs Industry: A099430 exceeded the KR Medical Equipment industry which returned -2.8% over the past year.
Return vs Market: A099430 underperformed the KR Market which returned 56.1% over the past year.
Price Volatility
| A099430 volatility | |
|---|---|
| A099430 Average Weekly Movement | 5.8% |
| Medical Equipment Industry Average Movement | 5.9% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 10.8% |
| 10% least volatile stocks in KR Market | 2.5% |
Stable Share Price: A099430 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A099430's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 125 | Hyun-Kyu Jung | www.bioplus.co.kr |
Bio Plus Co., Ltd engages in the research and development, production, and sale of bio products in South Korea. It offers dermal fillers under the SkinPlus – Hyal, Bio+ Dew, HyalDew, DeneB Classic, Stilea, and 3-Senses brand names. The company also provides medical products, including InterBlock, an absorbable anti-adhesion barrier; Synofil, a synovial fluid replacement; and Blad-Care, a solution to temporarily improve cystitis symptoms.
Bio Plus Co., Ltd Fundamentals Summary
| A099430 fundamental statistics | |
|---|---|
| Market cap | ₩348.07b |
| Earnings (TTM) | ₩16.21b |
| Revenue (TTM) | ₩89.16b |
Is A099430 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A099430 income statement (TTM) | |
|---|---|
| Revenue | ₩89.16b |
| Cost of Revenue | ₩30.18b |
| Gross Profit | ₩58.98b |
| Other Expenses | ₩42.77b |
| Earnings | ₩16.21b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 270.10 |
| Gross Margin | 66.15% |
| Net Profit Margin | 18.18% |
| Debt/Equity Ratio | 33.2% |
How did A099430 perform over the long term?
See historical performance and comparisonDividends
Does A099430 pay a reliable dividends?
See A099430 dividend history and benchmarks| Bio Plus dividend dates | |
|---|---|
| Ex Dividend Date | Dec 29 2025 |
| Dividend Pay Date | Apr 13 2026 |
| Days until Ex dividend | 39 days |
| Days until Dividend pay date | 144 days |
Does A099430 pay a reliable dividends?
See A099430 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/19 16:22 |
| End of Day Share Price | 2025/11/19 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bio Plus Co., Ltd is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyung Soo Kim | Hanwha Investment & Securities Co., Ltd. |
| Junghyun Kim | Kyobo Securities Co., Ltd |
| Jaehee Won | Shinhan Investment Corp. |